Search

Your search keyword '"Seiyo Honda"' showing total 3 results
Start Over Author "Seiyo Honda" Publication Year Range Last 10 years
3 results on '"Seiyo Honda"'

1. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.

Author

Tomohiro Koga, Akitomo Okada, Takaaki Fukuda, Toshihiko Hidaka, Tomonori Ishii, Yukitaka Ueki, Takao Kodera, Munetoshi Nakashima, Yuichi Takahashi, Seiyo Honda, Yoshiro Horai, Ryu Watanabe, Hiroshi Okuno, Toshiyuki Aramaki, Tomomasa Izumiyama, Osamu Takai, Taiichiro Miyashita, Shuntaro Sato, Shin-Ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Tomoki Origuchi, Hideki Nakamura, Kiyoshi Aoyagi, Katsumi Eguchi, Atsushi Kawakami, and Japanese RA Patients with RRP Study Group

Subjects
Medicine, Science
Abstract

To determine prognostic factors of clinically relevant radiographic progression (CRRP) in patients with rheumatoid arthritis (RA) achieving remission or low disease activity (LDA) in clinical practice.Using data from a nationwide, multicenter, prospective study in Japan, we evaluated 198 biological disease-modifying antirheumatic drug (bDMARD)-naïve RA patients who were in remission or had LDA at study entry after being treated with conventional synthetic DMARDs (csDMARDs). CRRP was defined as the yearly progression of modified total Sharp score (mTSS) >3.0 U. We performed a multiple logistic regression analysis to explore the factors to predict CRRP at 1 year. We used receiver operating characteristic (ROC) curve to estimate the performance of relevant variables for predicting CRRP.The mean Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) was 2.32 ± 0.58 at study entry. During the 1-year observation, remission or LDA persisted in 72% of the patients. CRRP was observed in 7.6% of the patients. The multiple logistic regression analysis revealed that the independent variables to predict the development of CRRP were: anti-citrullinated peptide antibodies (ACPA) positivity at baseline (OR = 15.2, 95%CI 2.64-299), time-integrated DAS28-ESR during the 1 year post-baseline (7.85-unit increase, OR = 1.83, 95%CI 1.03-3.45), and the mTSS at baseline (13-unit increase, OR = 1.22, 95%CI 1.06-1.42).ACPA positivity was the strongest independent predictor of CRRP in patients with RA in remission or LDA. Physicians should recognize ACPA as a poor-prognosis factor regarding the radiographic outcome of RA, even among patients showing a clinically favorable response to DMARDs.

Published
2017
Full Text
View/download PDF

2. Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy

Author

Tomohiro Koga, Munetoshi Nakashima, Toshiyuki Aramaki, Taiichiro Miyashita, Katsumi Eguchi, Takaaki Fukuda, Yukitaka Ueki, Toshihiko Hidaka, Takao Kodera, Naoki Iwamoto, Tomomasa Izumiyama, Yoshiro Horai, Hiroshi Okuno, Yuichi Takahashi, Kiyoshi Aoyagi, Tomonori Ishii, Hideki Nakamura, Shuntaro Sato, Osamu Takai, Tomoki Origuchi, Atsushi Kawakami, Kunihiro Ichinose, Akitomo Okada, Seiyo Honda, Ryu Watanabe, Shin-ya Kawashiri, and Mami Tamai

Subjects
Male, Risk, medicine.medical_specialty, Arthritis, Observational Study, Subgroup analysis, Blood Sedimentation, Arthritis, Rheumatoid, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Japan, Internal medicine, Medicine, Humans, 030212 general & internal medicine, Longitudinal Studies, Prospective Studies, Prospective cohort study, Aged, Autoantibodies, Pain Measurement, 030203 arthritis & rheumatology, biology, business.industry, C-reactive protein, General Medicine, Middle Aged, medicine.disease, Confidence interval, Surgery, C-Reactive Protein, Rheumatoid arthritis, Antirheumatic Agents, Cohort, biology.protein, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Disease Progression, Female, Joints, business, Cohort study, Research Article
Abstract

Supplemental Digital Content is available in the text, To determine prognostic factors of clinically relevant radiographic progression (CRRP) in patients with rheumatoid arthritis (RA) in clinical practice. We performed a multicenter prospective study in Japan of biological disease-modifying antirheumatic drug (bDMARD)-naive RA patients with moderate to high disease activity treated with conventional synthetic DMARDs (csDMARDs) at study entry. We longitudinally observed 408 patients for 1 year and assessed disease activity every 3 months. CRRP was defined as yearly progression of modified total Sharp score (mTSS) > 3.0 U. We also divided the cohort into 2 groups based on disease duration (

Published
2016

3. SAT0088 Prognostic Factors Toward Rapid Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving Treat to Target Strategy

Author

K Eguchi, A. Kawakami, Seiyo Honda, Ryu Watanabe, Takaaki Fukuda, Takao Kodera, Munetoshi Nakashima, Yukitaka Ueki, Hiroshi Okuno, Toshihiko Hidaka, Tomohiro Koga, Tomonori Ishii, Mami Tamai, Akitomo Okada, Yuichi Takahashi, and Kiyoshi Aoyagi

Subjects
musculoskeletal diseases, medicine.medical_specialty, business.industry, Radiography, Immunology, Treat to target, Subgroup analysis, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Surgery, Rheumatology, Rheumatoid arthritis, Internal medicine, Epidemiology, Immunology and Allergy, Medicine, In patient, business, Prospective cohort study, Subclinical infection
Abstract

Background Disease-modifying antirheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). Their effects are supposed to be different according to clinical condition, however, there have been few epidemiological reports of longitudinal investigation in RA patients captured in daily practice. Objectives To determine prognostic factors of radiographic progression (RRP) in patients with RA in clinical practice for achieving treat to target strategy. Methods We performed a Japanese multicenter prospective study on biological DMARDs (bDMARDs)-naive 887 RA patients with moderate to high disease activity or with radiographic bone erosion, treated with conventional synthetic DMARDs (csDMARDs) at study entry. We observed longitudinally these patients for 1 year and assessed Disease Activity Score in 28 joint (DAS28-ESR) every 3 months. RRP was defined as yearly progression of modified total Sharp score (mTSS) >3.0U. Furthermore, we divided into two groups based on disease duration ( Results RRP was found in 9.2% of patients. Multiple step-wise regression analysis revealed that disease duration (OR=0.92, 95% CI 0.86 to 0.99), time-integrated DAS28-ESR during 1 year (OR=1.04, 95% CI 1.01 to 1.06), CRP at baseline (OR=1.24, 95% CI 1.07 to 1.43), and introduction of bDMARDs (OR=0.12, 95% CI 0.03 to 0.55) are independent variables to predict the development of RRP. Intriguingly, our subgroup analysis has revealed that time-integrated DAS28-ESR during 1 year is not a significant predictor for RRP in early RA and the protective effect of bDMARDs toward RRP is evident in early RA patients. Conclusions RRP in RA patients treated with DMARDs is closely associated with persistent disease activity or early introduction of bDMARDs. Among early RA patient, subclinical RRP should be considered regardless of integrated disease activity. Disclosure of Interest None declared

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results